| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-11-10 | Eisai (Japan) | expansion of a subsidiary |
Cancer - Oncology - Neurological diseases | Establishment of a new subsidiary in the EU | ||
| 2014-11-07 | Felicitex Therapeutics (USA - MA) Selvita (Poland) | personalized cancer therapeutics including selective inhibitors of the cancer quiescence target kinase family | pancreatic, colon, ovarian, lung and hematopoietic tumors | development |
Cancer - Oncology | Development agreement |
| 2014-11-06 | AstraZeneca (UK) Aegerion Pharmaceuticals (USA - MA) | Myalept™ (metreleptin for injection) | leptin deficiency in patients with generalised lipodystrophy | product acquisition |
Metabolic diseases - Rare diseases | Product acquisition |
| 2014-11-06 | Paratek Pharmaceuticals (USA - MA) | vice-president, chief commercial officer | nomination | Infectious diseases | Nomination | |
| 2014-11-06 | Ipsen (France) Otonomy (USA - CA) | gacyclidine | tinnitus | licensing |
Otorhinolaryngology | Licensing agreement |
| 2014-11-06 | Eisai (Japan) | new Australian office in Melbourne | opening of new premises | Opening of new premises | ||
| 2014-11-06 | Bind Therapeutics (USA - MA) Merck&Co (USA - NJ) | Accurins based on a kinesin spindle protein (KSP) inhibitor and a polo-like kinase 1 (PLK1) inhibitor | development |
Cancer - Oncology | Development agreement | |
| 2014-11-05 | Genvec (USA - MD) Novartis (Switzerland) | hearing loss and balance disorders | R&D |
Otorhinolaryngology | Milestone | |
| 2014-11-04 | Sorin (Italy) | heart-lung machines, autotransfusion systems | Cardiovascular diseases | Opening of new premises | ||
| 2014-11-04 | Oncodesign (France) Isarna Therapeutics (Germany) | TGF-Beta therapeutics | R&D |
Cancer - Oncology - Ophtalmological diseases - Fibrotic diseases | R&D agreement | |
| 2014-11-04 | Carlina Technologies (France) GenBiotech (France) | sustained-release protein formulation | bone and cartilage repair | collaboration |
Bone diseases | Collaboration agreement |
| 2014-11-04 | AstraZeneca (UK) Janssen Research & Development - J&J (USA - NJ) Pharmacyclics (USA - CA) | MEDI4736 and Imbruvica® (ibrutinib) | haematological cancers including diffuse large B-cell lymphoma and follicular lymphoma | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2014-11-04 | AstraZeneca (UK) Pharmacyclics (USA - CA) | Imbruvica® (ibrutinib) and PI3 kinase pathway inhibitors | relapsed or refractory diffuse large B-cell lymphomas | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2014-11-04 | Bind Therapeutics (USA - MA) | chief medical officer | nomination | Cancer - Oncology | Nomination | |
| 2014-11-03 | Lonza (Switzerland) Celladon (USA - CA) | Mydicar® | advanced heart failure | manufacturing |
Cardiovascular diseases | Production agreement |
| 2014-11-03 | Isis Pharmaceuticals (USA - CA) GSK (UK) | ISIS-TTRRx, ISIS-GSK5Rx | transthyretin (TTR) amyloidosis | R&D |
Rare diseases - Genetic diseases - Infectious diseases - Ophtalmological diseases | Milestone |
| 2014-11-03 | Nordic Nanovector (Norway) | nomination |
Cancer - Oncology | Nomination | ||
| 2014-11-03 | Myriad Genetics (USA - UT) AbbVie (USA - IL) | Tumor BRACAnalysis CDx™ | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2014-11-03 | Atyr Pharma (USA - CA) | vice-president | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2014-11-02 | Covidien (Ireland) Spectranetics (USA - CO) | Stellarex™ drug coated angioplasty balloon (DCB) platform | peripheral arterial disease | product acquisition |
Cardiovascular diseases | Product acquisition |
